Notice: This company has been marked as potentially delisted and may not be actively trading. VIVUS (VVUS) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period VIVUS Shares Significant Regulatory Update on QSYMIA®October 28, 2024 | globenewswire.comVIVUS Announces Label Update for QSYMIA®October 23, 2024 | tmcnet.comVIVUS Provides Update on Pipeline and Program MilestonesJanuary 8, 2024 | markets.businessinsider.comMetaview announces Answers, the world's first conversational AI for the interview processMay 25, 2023 | it.tmcnet.comWhy aren’t new drugs that can help you lose weight more widely used? - MarketWatchOctober 2, 2022 | marketwatch.com'There's no way that patients are going to be able to afford that.' Why aren't new drugs that can help you lose weight more widely used? - MorningstarOctober 2, 2022 | morningstar.comErectile Dysfunction Drugs Market to Surpass Around USD 4079.9 Million by 2028, Says Brandessence Market Research - Yahoo FinanceSeptember 23, 2022 | finance.yahoo.comForm DEF 14A Catalent, Inc. For: Oct 27 - StreetInsider.comSeptember 16, 2022 | streetinsider.comObesity Management Market Expanding at an Impressive CAGR - GlobeNewswireSeptember 9, 2022 | globenewswire.comGlobal Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - Yahoo FinanceAugust 26, 2022 | finance.yahoo.comGlobal Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - PR NewswireAugust 26, 2022 | prnewswire.com2022-08-15 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - StockhouseAugust 17, 2022 | stockhouse.comPetros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - StreetInsider.comAugust 15, 2022 | streetinsider.comKaléo Announces Executive Appointments and New Government Business Unit - Yahoo FinanceAugust 11, 2022 | finance.yahoo.comIcahn Enterprises L P : Reports Second Quarter 2022 Financial Results - Form 8-K - Marketscreener.comAugust 5, 2022 | marketscreener.comGlobal Cystic Fibrosis Market Report 2022-2030: CFTR Modulators Segment to Dominate the Market - BenzingaAugust 2, 2022 | benzinga.comGlobal Cystic Fibrosis Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts 2020-2030 - ResearchAndMarkets.com - Business WireJuly 31, 2022 | businesswire.comGlobal Achondroplasia Market to Surpass US$ 1100.97 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswireJuly 26, 2022 | globenewswire.comThe best stock investing strategy for 2022: Don’t buy the dip, buy the dividend - FortuneJuly 14, 2022 | fortune.comBioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - Yahoo FinanceJuly 5, 2022 | finance.yahoo.comBioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - StreetInsider.comJuly 5, 2022 | streetinsider.comOverweight Treatment Market estimated to surge ahead at a CAGR of 7.9% by the end of 2032 - Persistence M - BenzingaJune 8, 2022 | benzinga.com2022-05-16 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - StockhouseMay 16, 2022 | stockhouse.comIcahn Enterprises (IEP) Q1 2022 Earnings Call Transcript - The Motley FoolMay 6, 2022 | fool.comPetros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GuruFocus.comMay 3, 2022 | gurufocus.comPetros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US - GlobeNewswireMay 3, 2022 | globenewswire.comPetros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - GuruFocus.comApril 27, 2022 | gurufocus.comPetros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology - Yahoo FinanceApril 26, 2022 | finance.yahoo.comPetros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil) - GlobeNewswireApril 19, 2022 | globenewswire.comDiet Pills Market Size Worth $2.27Bn, Globally, by 2028 at 10.4% CAGR - Exclusive Report by The Insight Partners - PR NewswireApril 5, 2022 | prnewswire.comGlobal Obesity Treatment Market Research Report to 2027 - Emerging Demand for Minimally Invasive Methods Presents Opportunities - ResearchAndMarkets.com - Business WireApril 1, 2022 | businesswire.comPETROS PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comMarch 31, 2022 | marketscreener.comPhosphodiesterase Inhibitors Market: Industry Analysis and Opportunity Assessment 2028 - Benzinga - BenzingaMarch 30, 2022 | benzinga.comErectile Dysfunction (ED) Drugs Market: 4.76% YOY Growth Rate in 2022 | By Product (oral drugs, topical drugs, and others) and Geography | Growth, Trends, and Forecasts (2022 - 2026) - PR NewswireMarch 23, 2022 | prnewswire.comDrugs For Erectile Dysfunction Global Market Report 2022 - Yahoo FinanceMarch 16, 2022 | finance.yahoo.comEquillium : Announces Appointment of Barbara Troupin to Board of Directors - Form 8-K - Marketscreener.comMarch 3, 2022 | marketscreener.comWhy Zscaler Stock Plunged Today - NasdaqFebruary 26, 2022 | nasdaq.comIcahn Enterprises (IEP) Q4 2021 Earnings Call Transcript - The Motley FoolFebruary 25, 2022 | fool.comIcahn Enterprises L.P. (IEP) CEO David Willetts on Q4 2021 Results - Earnings Call Transcript - Seeking AlphaFebruary 25, 2022 | seekingalpha.comErectile Dysfunction Drugs Market size worth $ 2952 Million, Globally, by 2028 at -3.4% CAGR: Verified Market Research® - Yahoo FinanceFebruary 11, 2022 | finance.yahoo.comPETROS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (form 8-K) - marketscreener.comJanuary 21, 2022 | marketscreener.comPetros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug STENDRA® (avanafil) - PRNewswireJanuary 19, 2022 | prnewswire.comAytu BioPharma Appoints Mark Oki as Chief Financial Officer - StreetInsider.comJanuary 4, 2022 | streetinsider.comForm 424B3 Petros Pharmaceuticals, - StreetInsider.comDecember 20, 2021 | streetinsider.comPetros Pharmaceuticals Announces Positive Over-the-Counter (OTC) Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA® (avanafil) - PRNewswireDecember 10, 2021 | prnewswire.comForm 424B5 Petros Pharmaceuticals, - StreetInsider.comDecember 2, 2021 | streetinsider.comPetros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update - PRNewswireNovember 15, 2021 | prnewswire.comAnnouncement of Retirement of Judge Christopher Sontchi - marketscreener.comNovember 15, 2021 | marketscreener.comPetros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease - PRNewswireNovember 9, 2021 | prnewswire.comObesity Treatment Market Research Report by Drugs, by Surgery & Devices, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo FinanceNovember 8, 2021 | finance.yahoo.com Get VIVUS News Delivered to You Automatically Sign up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address VVUS Media Mentions By Week VVUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VVUS News Sentiment▼0.000.86▲Average Medical News Sentiment VVUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VVUS Articles This Week▼00▲VVUS Articles Average Week Get VIVUS News Delivered to You Automatically Sign up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Eli Lilly and Company News Today Johnson & Johnson News Today AbbVie News Today Merck & Co., Inc. News Today Pfizer News Today Bristol-Myers Squibb News Today Zoetis News Today Royalty Pharma News Today Jazz Pharmaceuticals News Today Corcept Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VVUS) was last updated on 1/5/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VIVUS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VVUS Stock Alerts